Japan's Advantest expects 6% annual profit growth as AI boosts testing


FILE PHOTO: Advantest's logo is pictured in Tokyo, Japan June 4, 2024. REUTERS/Sam Nussey/File Photo

TOKYO (Reuters) -Japanese chip testing equipment maker Advantest forecast on Friday its operating profit to grow 6% next fiscal year, buoyed by demand for its testing tools for chips used in the artificial intelligence tasks.

Advantest "does not recognise more than a minor direct impact" from tariffs but the business environment is increasingly uncertain, the company said in an earnings release.

"We are talking a cautious approach, particularly beyond what we can see in the first half," CEO Douglas Lefever told an earnings briefing.

The company reported operating profit of 228.2 billion yen ($1.59 billion) for the year ended March 31, up sharply from 81.6 billion yen in fiscal year 2024.

Advantest expects an operating profit of 242 billion next fiscal year.

It said it would buy back about 19 million shares for up to 70 billion yen.

Its shares closed up 4.6% ahead of earnings on Friday and have fallen around 33% this year so far.

($1 = 143.2400 yen)

(Reporting by Sam Nussey; Editing by Rashmi Aich and Tomasz Janowski)

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Tech News

Exclusive-Google works to erode Nvidia's software advantage with Meta's help
Brazil to get satellite internet from Chinese rival to Starlink in 2026
US gaming platform Roblox pledges changes to get Russian ban lifted
Oracle's $10 billion Michigan data center in limbo after Blue Owl funding talks stall, FT reports
Coursera to buy Udemy, creating $2.5 billion firm to target AI training
Factbox-By the numbers: How the Netflix and Paramount bids for Warner Bros stack up
Warner Bros Discovery board rejects rival bid from Paramount
Analysis-Qatar bets on cheap power to catch up in Gulf AI race
Analysis-Crypto investors show caution, shift to new strategies after crash
OpenAI’s ChatGPT updated to�make images better and faster

Others Also Read